- Distinguishing Rathke's cleft cysts from craniopharyngiomas is difficult because squamous metaplasia (the transformation of one cell type to another) creates histological overlap.
- Researchers retrospectively analyzed 69 cases of Rathke's cleft cysts using immunohistochemistry and genetic sequencing to identify specific molecular mutations.
- Seven cases (10.1 percent) tested positive for the BRAF V600E mutation and showed significantly worse progression-free survival (p = 0.023).
- The authors concluded that BRAF V600E testing effectively identifies misclassified papillary craniopharyngiomas that require more aggressive clinical management.
- Clinicians should perform molecular testing on all Rathke's cleft cysts to ensure accurate diagnosis and guide appropriate adjuvant therapy.
The Diagnostic Dilemma of the Sellar Region
Clinicians managing sellar and suprasellar masses frequently face a diagnostic challenge in distinguishing between Rathke's cleft cysts and craniopharyngiomas due to their shared embryological origin from Rathke's pouch [1, 2]. While Rathke's cleft cysts are generally benign lesions that may only require observation or simple fenestration, craniopharyngiomas are more aggressive tumors characterized by higher recurrence rates and complex adherence to neurovascular structures [3, 4]. The presence of squamous metaplasia, the transformation of one mature cell type into another, within a cyst wall can further obscure the diagnosis because this feature is histologically similar to the stratified squamous epithelium found in papillary craniopharyngiomas [5, 6]. Misidentification can lead to inadequate surgical resection or insufficient postoperative surveillance, particularly since papillary variants are driven by distinct molecular pathways [7, 8]. To resolve this ambiguity, researchers recently investigated whether specific genetic markers can definitively separate benign cysts from lesions likely to behave more aggressively.
Molecular Profiling of Sellar Lesions
To address the diagnostic ambiguity between these sellar masses, researchers at Beijing Tiantan Hospital conducted a retrospective analysis of 383 Rathke's cleft cysts diagnosed between January 2015 and May 2024. Both Rathke's cleft cysts and craniopharyngiomas originate from remnants of Rathke's diverticulum, the embryonic pouch that eventually forms the anterior pituitary gland. From the initial cohort, 69 cases met the final inclusion criteria, comprising 61 primary and 8 recurrent cases. The anatomical distribution revealed that 52 lesions (75.4%) were located in the intrasellar region, while 9 cases (13.0%) were situated in the suprasellar region, and 8 cases (11.6%) involved both compartments. The researchers utilized immunohistochemistry, a tissue-staining technique that uses antibodies to detect specific cellular antigens, to screen for BRAF V600E and CTNNB1 mutations. These mutations serve as distinguishing genetic markers for papillary craniopharyngioma and adamantinomatous craniopharyngioma, respectively. To ensure diagnostic precision, all BRAF results were further validated using Sanger sequencing, a targeted method for determining the exact nucleotide sequence of a DNA segment. By mapping clinical and radiological data against these molecular profiles, the study sought to determine if the BRAF V600E mutation, which causes constitutive activation of cellular signaling pathways, or CTNNB1 mutations, which lead to the nuclear accumulation of beta-catenin protein, could provide a definitive classification for lesions that mimic standard cysts.
Histological Overlap and Genetic Reclassification
Histological analysis of the cohort revealed that 39 cases (56.5%) exhibited epithelial squamous metaplasia, a process where the normal ciliated columnar epithelium of a Rathke's cleft cyst is replaced by stratified squamous cells. This cellular shift is clinically significant because it creates substantial histological overlap with papillary craniopharyngiomas, frequently leading to diagnostic ambiguity during routine microscopic examination. To differentiate these lesions from the adamantinomatous variant of craniopharyngioma, the researchers screened for the nuclear accumulation of beta-catenin, a protein that translocates to the nucleus in the presence of CTNNB1 mutations. The study found that no nuclear beta-catenin accumulation was detected in any of the cases, effectively ruling out the adamantinomatous subtype in this patient group. However, molecular screening identified BRAF V600E expression in 7 cases (10.1%), with the expression occurring exclusively within the areas of squamous metaplasia. Beyond the presence of the mutation itself, these BRAF V600E-positive cases demonstrated elevated Ki-67 indices, a standard marker of cellular proliferation indicating a higher rate of tumor growth. This proliferative activity was specifically concentrated at the basal layer of the metaplastic epithelium, suggesting these regions are the primary drivers of lesion expansion. Based on the combination of these molecular and histological findings, the researchers reclassified the 7 BRAF V600E-positive cases as papillary craniopharyngiomas. For the practicing neurosurgeon or endocrinologist, this highlights that what initially appears to be a benign cyst on standard pathology may actually represent a more aggressive neoplastic process requiring a different surgical approach.
Clinical Implications for Postoperative Management
The clinical trajectory of patients with these sellar lesions depends heavily on their underlying molecular profile. A Kaplan-Meier analysis, a statistical method used to estimate the proportion of patients who remain free of disease progression over time, demonstrated significantly worse progression-free survival in BRAF V600E-positive cases compared to wild-type cases (p = 0.023). This finding indicates that patients harboring the BRAF mutation experience tumor recurrence or progression much earlier than those with the standard genetic profile. Because these mutation-positive lesions behave more like aggressive papillary craniopharyngiomas than benign cysts, identifying the BRAF V600E variant serves as a critical prognostic indicator that should directly dictate postoperative follow-up intervals. Given the potential for an apparent Rathke's cleft cyst to harbor the molecular drivers of a more aggressive neoplasm, the researchers recommend BRAF V600E testing for all Rathke's cleft cyst cases. This diagnostic step is essential because the presence of squamous metaplasia alone is insufficient to predict clinical behavior. By implementing universal molecular screening, clinicians can identify the subset of patients whose cysts are likely to transform or recur. For those identified as BRAF V600E-positive, the authors advise close monitoring of tumor progression or the consideration of adjuvant therapies, such as radiotherapy or targeted molecular treatments, to manage the increased risk of recurrence. Ultimately, this molecular stratification allows physicians to spare low-risk patients from unnecessary interventions while ensuring that high-risk patients receive the intensified surveillance required for their specific biological profile.
References
1. Cherem-Kibrit M, Spektor S, Kaye AH, et al. Challenges in intraoperative differentiation of craniopharyngioma and Rathke cleft cyst on endoscopic visualization.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2025. doi:10.1016/j.jocn.2024.111015
2. Hacıoğlu A, Tekiner H, Altinoz MA, et al. Rathke’s cleft cyst: From history to molecular genetics. Reviews in Endocrine and Metabolic Disorders. 2025. doi:10.1007/s11154-025-09949-6
3. Cuny T, Reynaud R, Raverot G, et al. Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement. Annales d Endocrinologie. 2024. doi:10.1016/j.ando.2024.07.002
4. Calandrelli R, D’Apolito G, Martucci M, et al. Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic–Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview. Cancers. 2024. doi:10.3390/cancers16142532
5. Mattheisen H, Tavakoli S, Mrachek EK, Cheok S, Zwagerman NT. Transformation Versus Ascertainment Bias of a Suprasellar Lesion: A Histopathologic Conundrum of BRAF V600E Positive Papillary Craniopharyngioma Versus Rathke's Cleft Cyst with Squamous Metaplasia: A Systematic Review. Journal of Neurological Surgery Reports. 2025. doi:10.1055/a-2751-8340
6. Candy NG, Mignone E, Quick E, et al. The role of BRAF testing of Rathke’s cleft cysts to identify missed papillary craniopharyngioma. Pituitary. 2025. doi:10.1007/s11102-025-01501-8
7. Javidialsaadi M, Luy DD, Smith H, Cecia A, Yang SD, Germanwala AV. Advances in the Management of Craniopharyngioma: A Narrative Review of Recent Developments and Clinical Strategies. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14041101
8. Tsukamoto T, Miki Y. Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 2. Neoplasms other than PitNET and tumor-mimicking lesions. Japanese Journal of Radiology. 2023. doi:10.1007/s11604-023-01407-0